TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Alvotech announces European launch of first-in-market biosimilar to Simponi® (golimumab) globally by partner Advanz Pharma

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Alvotech
Alvotech announces European launch of first-in-market biosimilar to Simponi® (golimumab) globally by partner Advanz Pharma

Alvotech announced the European launch of Gobivaz® (golimumab), the first-to-market biosimilar to Simponi® globally, commercialized by partner Advanz Pharma. The launch is supported by an NHS England tender award in the United Kingdom, which provides a defined framework for adoption within NHS services. Gobivaz is manufactured at Alvotech's Iceland facility and is available in the same presentations and dosage forms as the reference product.

Insights
ALVO   positive

Alvotech achieved a significant milestone as the first company to launch a biosimilar to Simponi globally, secured NHS England tender award supporting market adoption, and demonstrated successful regulatory approval and manufacturing capabilities. This represents competitive advantage and revenue generation opportunity.